Hostname: page-component-857557d7f7-8wkb5 Total loading time: 0 Render date: 2025-11-22T21:48:53.040Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluation of Vancomycin Use in a Pediatric Teaching Hospital Based on CDC Criteria

Published online by Cambridge University Press:  02 January 2015

Beth A. Logsdon ,
Kelley R. Lee ,
Gary Luedtke  and
Fred F. Barrett
Get access Rights & Permissions [Opens in a new window]

Abstract

This study was performed to determine whether van-comycin use at our pediatric hospital was consistent with modified Centers for Disease Control and Prevention guidelines. Vancomycin use was inappropriate in 54% of patients. Inappropriate use briefly decreased by 14% after educational efforts. Further education regarding van-comycin use was deemed necessary and is continuing.

Information

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 18 , Issue 11 , November 1997 , pp. 780 - 782
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1997 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR 1993;42:597–599.Google Scholar
2. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Advisory Committee. MMWR 1995;44(RR 12):1–13.Google Scholar
3. Chesney, PJ, Wilimas, JA, Wang, WC. Use of vancomycin for non-meningeal invasive pneumococcal infections. J Pediatr 1996;128:862–863. Letter.Google Scholar
4. Rubin, LG, Tucci, V, Cercenado, E, Eliopoulos, G, Isenberg, HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;13:700–705.Google Scholar
5. Fletcher, CV, Giese, RM, Rodman, JH. Pharmacist interventions to improve prescribing of vancomycin and tobramycin. Am J Hosp Pharm 1986;43:2198–2202.Google Scholar
6. McCormack, JP, Lynd, LD, Pfeifer, NM. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service. Canadian Journal of Hospital Pharmacy 1986;42:3–9.Google Scholar
7. Misan, GMH, Martin, ED, Smith, ER, Somogyi, AA, Bartholomeusz RCA, Bochner E Drug utilization review in a teaching hospital: experience with vancomycin. Eur J Clin Pharmacol 1990;39:457–461.Google Scholar
8. Johnson, SV, Hoey, LL, Vance-Bryan, K, Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy 1995;15:579–585.Google Scholar
9. Evans, ME, Kortes, KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol 1996;17:356–359.Google Scholar
10. Logsdon, BA, Lee, KR, Barrett FE Correct dosing of vancomycin in infants and children. Pediatrics 1995;96:1177. Letter.Google Scholar